Ozone Therapy Marketing Compliance Rules: The FDA Position on Medical Ozone and the Phrases That Trigger Action

Most modality-specific marketing rules come from years of warning letters, settlements, and case law that have to be stitched together. Ozone is the rare modality where the FDA has stated its position out loud, in 21 CFR 801.415, and almost nobody writing ozone clinic copy has read it. That regulation is the frame for everything else in this post.

This is a practical compliance note for clinics offering medical ozone in any of its common formats - IV ozone (major autohemotherapy, MAH), ten-pass ozone, ozone insufflation (rectal or vaginal), ozonated saline, intra-articular ozone, and topical ozonated oils. The rules apply across formats, but the specific language patterns vary.

Pitfall 1: Treating the FDA position as silent

The single most common ozone-marketing mistake is writing as if the FDA has no position on ozone. The FDA has a position. It is adverse. Ignoring it does not make it go away, and it is the first thing an agency reviewer or a state attorney general will cite if marketing is challenged.

Pitfall 2: Disease-treatment claims

Ozone clinics often list indications: Lyme disease, autoimmune conditions, chronic infections, cancer, post-COVID syndromes, herpes, hepatitis, autism. Every one of those is a disease- treatment claim, and every one is in tension with the FDA position above. The combination - a substance the FDA says has no useful medical application, paired with a disease-name list - is the framing the agency and the FTC have actioned in adjacent categories.

Pitfall 3: COVID-era and viral-illness framing

During and after the COVID-19 pandemic, the FTC and FDA both issued warning letters to ozone marketers making COVID-related claims. Long-COVID and post-viral syndrome language has the same risk profile. Even immune-support framing in the context of chronic viral conditions is heard by regulators as the same claim with extra adjectives.

Pitfall 4: Outcome and safety overstatement

Pitfall 5: Device language for non-cleared devices

Ozone generators used in clinic settings are typically not cleared or approved by the FDA for medical use. Marketing copy that calls the device medical-grade or FDA-registered without clear context is heard as implying device clearance the device does not have. Establishment registration is not 510(k) clearance; the two are different things.

What a defensible ozone program page does

• Names the FDA position (21 CFR 801.415) in the lead, not the footer.
• Describes the formats offered (IV, insufflation, ten-pass, etc.) factually, without disease-indication lists.
• Discloses the format-specific risks honestly, including the fact that inhalation is dangerous and any IV format carries IV-specific risks.
• Frames patient interest as a clinical conversation, not a shopping decision.
• Avoids treatment, therapy-for, cure, powerful, safest, and the disease-name list pattern.

Do and don’t

• Do cite 21 CFR 801.415 by name in the FDA- position paragraph. It is more credible than paraphrasing it.
• Do describe the format - MAH, insufflation, ten-pass - in factual procedural language.
• Do route clinical questions to the consultation.
• Don’t publish disease-indication lists in public marketing.
• Don’t use FDA-registered or medical- grade to imply device clearance the device does not have.
• Don’t reuse ozone-COVID marketing copy from 2020-2022 - that entire era is the worked example for what not to do.

Adjacent reading

Ozone clinics frequently offer peptide programs alongside ozone services. The compliance frames are different but the compounded-product layer rhymes; see BPC-157 peptide marketing and the 503A pharmacy layer for the parallel.